Poly (ADP-ribose) Polymerase Promoter Hypermethylation Predispose Females to Breast Cancer

Hussein Sabit, Shaimaa Nazir, Shaimma Abdel-Ghany, Osama Said, Eman Wagih, Omnia Badawy, Ashraf Alzayyat, Amany Alqosaibi, Emre Cevik, Huseyin Tombuloglu, Mokhtar Elzawahri

Abstract


Being the most common cause of female deaths worldwide, breast cancer (BC) is intensively studied over the last two decades. In the present investigation, we evaluated the promoter methylation of three cancer-related genes; PARP-1, p21, and Rb in 10 bi-matched BC samples included the core tumor and healthy tissue. H&E-stained histopathological sectioning revealed grade 2 and grade 3 tumor cells. Methylation-specific PCR (MSP) was performed using methylated (M) and unmethylated (U) primers for the three genes understudy. Histone acetyltransferase was measured in tumor and healthy tissues. A variation in the methylation state of the promoter region of the three genes were observed in core tumor and healthy tissue. PARP and Rb were hypermethylated in tumor tissues while p21 was less methylated. HAT activities were positively correlated with the methylation pattern observed in healthy tissues, as HAT was highly expressed in healthy vs. tumor tissues. The obtained data might indicate that patients might be at risk of BC recurrence after being subjected to mastectomy. These data could be employed as a core in epigenetic-based data mining to establish a model for predicting the breast cancer-predisposed patients. However, further investigations are needed to fulfill this goal. 


Full Text:

PDF (FULL TEXT)

References


Bai P, Canto C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab 2012;16: 290–95.

Carioli G, Malvezzi M, Rodriguez T, Bertuccio P, Negri E, La Vecchia C. Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia. The Breast 2018; 37: 163e169.

Chi HC, Tsai CY, Tsai MM, Lin KH. Impact of DNA and RNA Methylation on Radiobiology and Cancer Progression. Int. J. Mol. Sci. 2018;19(2): 555.

Cock-Rada A, Weitzman JB. The methylation landscape of tumor metastasis. Biol. Cell 2013;105, 73–90.

Coppede F, Tannorella P, Stoccoro A, Chico L, Siciliano G, Bonuccelli U, et al. Methylation analysis of DNA repair genes in Alzheimer's disease. Mech Ageing Dev 2017;161: 105-11.

Dharwal V, Naura AS. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice Biochemical Pharmacology 2018;150: 24–34.

Friedmann DR, Marmorstein R. Structure and mechanism of non-histone protein acetyltransferase enzymes. FEBS J. 2013;280(22): 5570-81.

Gao A, Zuo X, Liu Q, Lu X, Guo W, Tian L. Methylation of PARP-1 promoter involved in the regulation of benzene-induced decrease of PARP-1 mRNA expression. Toxicology Letters 2010;195: 114–18.

Garber K. PARP inhibitors bounce back. Nat Rev Drug Discov 2013;12(10): 725-7.

Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25: 5220–27.

Gong C, Tao G, Yang L, Liu J, Liu Q, Li W, et al. Methylation of PARP-1 promoter involved in the regulation of nano-SiO2-induced decrease of PARP-1 mRNA expression Toxicology Letters 2012;209: 264–69.

Hajiloo M, Damavandi B, HooshSadat M, Sangi F, Mackey JR, Cass CE, et al. Breast cancer prediction using genome wide single nucleotide polymorphism data. BMC Bioinformatics 2013;14,13: S3.

Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7(6): 340-7.

Lister R, Pelizzola M, Dowen RH, Hawkins RD, Hon G, Tonti-Filippini J, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009;462: 315–22.

Liu H, Dibling B, Spike B, Dirlam A, Macleod K. New roles for the RB tumor suppressor protein. Curr. Opin. Genet. Dev 2004;14: 55–64.

Lopes-Coelho F, Andre S, Felix A, Serpa J. Breast cancer metabolic cross-talk: Fibroblasts are hubs and breast cancer cells are gatherers of lipids Molecular and Cellular Endocrinology 2018; 462: 93e106.

Lu R, Wang GG. Tudor: a versatile family of histone methylation 'readers'. Trends Biochem Sci. 2013;38(11): 546-55.

McGrath J, Trojer P. Targeting histone lysine methylation in cancer. Pharmacol Ther. 2015;150: 1-22.

Moussa RS, Kovacevic Z, Bae DH, Lane DJR, Richardson DR. Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by the chelator, Dp44mT. BBA - General Subjects 2018;1862,(3): 761–74.

Murphree AL, Benedict WF. Retinoblastoma: clues to human oncogenesis. Science 1984;223, 1028–33.

Nishiyama H, Gill JH, Pitt E, Kennedy W, Knowles MA. Negative regulation of G1/S transition by the candidate bladder tumour suppressor gene DBCCR1. Oncogene 2001;20: 2956–64.

Nowsheen S, Aziz K, Tran PT, Gorgoulis VG, Yang ES, Georgakilas AG. Epigenetic inactivation of DNA repair in breast cancer Cancer Letters 2014;342: 213–22.

Park SY, Kwon HJ, Lee HE, Ryu HS, Kim S, Kim JH, et al. Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011,458: 73–84.

Pérez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics 2017;12(5): 323–39.

Portela A, Liz J, Nogales V, Setien F, Villanueva A, Esteller M. DNA methylation determines nucleosome occupancy in the 5'-CpG islands of tumor suppressor genes. Oncogene 2013;32: 5421–28.

Sandoval-Basilio J, González-González R, Bologna-Molina R, Isiordia-Espinoza M, Leija-Montoya G, Alcaraz-Estrada SL, Serafín-Higuera I, González-Ramírez J, Serafín-Higuera N. Epigenetic mechanisms in odontogenic tumors: A literature review. Arch Oral Biol. 2018;87: 211-7.

Shweta D, Jailkhani N, Midha MK, Rao KVS, Kumar A. Rb interactome data and its modulations during cell cycle progression in HEK 293 cells. Data in Brief 2018;17: 604–9.

Taniguchi K, Matsumura K, Kageyama S, Li H, Ashihara E, Chano T. Prohibitin-2 is a novel regulator of p21WAF1/CIP1 induced by depletion of g-glutamylcyclotransferase. Biochemical and Biophysical Research Communications 2018;496: 218e224.

Ushijima T, Asada K. Aberrant DNA methylation in contrast with mutations. Cancer Sci. 2010;101(2): 300-5.

Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, et al. Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Rep 2018;22(5): 1185-99.

You Y, Sawikowska A, Neumann M, Posé D, Capovilla G, Langenecker T, Neher RA, Krajewski P, Schmid M. Temporal dynamics of gene expression and histone marks at the Arabidopsisshoot meristem during flowering. Nat Commun. 2017;17,8: 15120.

Yu L, Liang Y, Cao X, Wang X, Gao H, Lin SY, et al. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer. Oncogene 2017;36(20): 2910-8.




DOI (PDF (FULL TEXT)): http://dx.doi.org/10.22034/APJCB.2018.3.4.105

Refbacks

  • There are currently no refbacks.


Copyright (c) 2019 Asian Pacific Journal of Cancer Biology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


 

  

PORTICO

 

Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention